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Abstract
Background: The combination of gemcitabine (GEM) and S-1, an oral 5-fluorouracil (5-FU) derivative, has been
shown to be a promising regimen for patients with unresectable pancreatic cancer.
Methods: Six patients with advanced pancreatic cancer were enrolled in this pharmacokinetics (PK) study. These
patients were treated by oral administration of S-1 30 mg/m
2 twice daily for 28 consecutive days, followed by a
14-day rest period and intravenous administration of GEM 800 mg/m
2 on days 1, 15 and 29 of each course. The PK
parameters of GEM and/or 5-FU after GEM single-administration, S-1 single-administration, and co-administration of
GEM with pre-administration of S-1 at 2-h intervals were analyzed.
Results: The maximum concentration (Cmax), the area under the curve from the drug administration to the
infinite time (AUCinf), and the elimination half-life (T1/2) of GEM were not significantly different between GEM
administration with and without S-1. The Cmax, AUCinf, T1/2, and the time required to reach Cmax (Tmax) were
not significantly different between S-1 administration with and without GEM.
Conclusion: There were no interactions between GEM and S-1 regarding plasma PK of GEM and 5-FU.
Background
Unresectable pancreatic cancer is known to have a poor
prognosis, with most patients dying within several
months of diagnosis. However, recent progress in che-
motherapy using gemcitabine (GEM) for this disease has
improved patient survival. A number of phase III clinical
trials have been performed to determine the GEM regi-
mens that lead to the greatest increases in survival com-
pared with GEM monotherapy. To date, only one
regimen has been shown to yield significantly longer
survival periods than GEM alone in phase III studies:
GEM with erlotinib, an epidermal growth factor recep-
tor (EGFR)-targeting agent [1].
S-1 is an oral fluoropyrimidine derivative that contains
tegafur (a 5-FU prodrug) and a reversible competitive
dihydropyrimidine dehydrogenase (DPD) inhibitor, 5-
chloro-2,4-dihydrogenase (CDHP). As DPD is a rate-
limiting enzyme that degrades 5-FU, CDHP is expected
t oe n h a n c et h ec y t o t o x i c i t yo f5 - F Ub yp r o l o n g i n gh i g h
5-FU concentrations in blood and tumor tissues [2]. In
Japan, S-1 has been clinically used as a first-line che-
motherapeutic agent for pancreatic cancer since being
approved for national health insurance coverage in
2006. A phase II study of S-1 for 40 patients with meta-
static pancreatic cancers resulted in the response rate of
37.5% and the overall survival time of 9.2 months [3].
As the efficacy of S-1 monotherapy against pancreatic
cancer is not satisfactory, numerous studies using S-1
combined with GEM have been conducted. Two phase I
studies and two phase II studies of the combination
therapy showed promising efficacy and acceptable
adverse events [4-7]. A phase III study comparing GEM
+S-1 vs. S-1 monotherapy vs. GEM monotherapy for
metastatic pancreatic cancer (GEST study) has been
underway in Japan and Taiwan since 2007. In contrast
to the large number of clinical trials regarding GEM+S-
1, pharmacokinetic studies to investigate the interaction
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the first study to compare the plasma pharmacokinetics
(PK) of GEM and 5-FU after GEM+S-1 to those after
single administration of individual drugs in the same
patients.
Methods
Eligibility
Patients under 80 years of age with a diagnosis of unre-
sectable pancreatic cancer were eligible. Eastern Coop-
e r a t i v eO n c o l o g yG r o u pp e r f o r m a n c es t a t u s( P S )≤ 2,
and life expectancy ≥ 12 weeks were required. Patients
were required to have measurable or assessable disease
and to have had no chemotherapy or immunotherapy
before enrolling. Other eligibility requirements included
adequate bone marrow function (Hb ≥ 9.0 g/dl, white
blood cells between 4,000 and 12,000/μl, neutrophils ≥
2,000/μl and platelets ≥ 100,000/μl), total bilirubin ≤ 2
mg/dl, AST and ALT ≤ 100 IU/l, alkali phosphatase ≤ 2
times the upper normal level, and BUN and serum crea-
tinine ≤ the upper normal level.
Patients
A total of six patients with unresectable pancreatic can-
cer diagnosed by imaging studies including abdominal
dynamic computed tomography were enrolled in this
study between April and June, 2007. Mean age ± stan-
dard deviation was 68 ± 4 years (range, 63-73 years).
One case had liver metastasis, three had peritoneal
metastasis, and two had tumors involving the celiac
and/or superior mesenteric arteries. Informed consent
from all participants was obtained. The institutional
review board for human experimentation in our hospital
approved the study protocols.
Treatment
S-1 (Taiho Pharmaceutical Co., Tokyo, Japan) was admi-
nistered orally at a dose of 30 mg/m
2 twice daily after a
meal. One course consisted of consecutive administra-
tion for 28 days, followed by a 14-day rest period. GEM
800 mg/m
2 in 100 ml normal saline was administered
intravenously (i.v.) for 30 min on days 1, 15 and 29 of
each course. The regimen was set by referring to pre-
vious clinical trials [4-7].
Sample collection
Blood samples were drawn on days 1, 3 and 15 of the
first course. The object of sampling at day 1 was to
monitor the plasma PK of GEM after administration of
GEM alone. Subsequently, S-1 administration on day 1
of the first course began at the evening after blood sam-
plings. The object of sampling at day 3 was to monitor
t h ep l a s m aP Ko f5 - F Ua f t e ra d m i n i s t r a t i o no fS - 1
alone. The object of sampling at day 15 was to examine
the changes in individual drug PK after other drug
administration. For this purpose, S-1 was administered 2
h before administration of GEM (Figure 1), when the
plasma concentration of 5-FU had increased substan-
tially [8]. Each peripheral blood sample (2 ml) was col-
lected into a heparinized tube that contained 20 μlo f
tetrahydrouridine (a cytidine deaminase competitive
inhibitor) solution at a concentration of 10 mg/ml. The
samples were centrifuged at 3000 rpm for 10 min.
Plasma was stored at -20°C until the measurement of 5-
FU and GEM concentrations.
GEM assay
The high-performance liquid chromatography (HPLC)
system consisted of a Waters 2690 liquid chromato-
graph separation module and a Waters SMH column
heater (all from Waters (MA, USA). The Atlantis
R dC18
column (150 × 4.6 mm; particle size, 5 μm; Waters) was
used for the peak separation of GEM. The HPLC mobile
phase was a solution of 5 mM phosphate buffer (pH
7.2). The ultraviolet detector was a Waters 2487
(Waters), and was used at 272 nm. Plasma samples were
deproteinized with 20% TCA, and the supernatants were
filtered using Ultrafree-MC (Nihon Millipore, Tokyo,
Japan) with pore diameters of 0.20 μm. Aliquots of 20
μl were injected into the HPLC system. The quantitative
range of this method was 50-40000 ng/ml.
5-FU assay
The high-performance liquid chromatographic-mass
spectrometry (LC/MS) system consisted of a Micromass
ZQ-2000 mass spectrometer, a Waters 2695 liquid chro-
matograph separation module and a Waters SMH col-
umn heater (all from Waters). The Atlantis
R dC18
column (150 × 2.1 mm; particle size, 5 μm; Waters) was
used for the peak separation of 5-FU. The HPLC mobile
phase was a solution mixed purified water and acetoni-
trile. The mass spectrometer was used in the negative
ESI mode. The detector was used in SIR mode with a
selected ion recording procedure at m/z = 128.9 for 5-
F Ua n da tm / z=1 3 0 . 9f o r5 - F U -
15N2.T op l a s m as a m -
ples, internal standard solution (including 5-FU-
15N2)
was added, and was then extracted with ethyl acetate.
The organic layer was evaporated to dryness under a
stream of nitrogen. The residue was dissolved in purified
water, and after vortex mixing, the mixture was filtered
using Ultrafree-MC (Nihon Millipore) with pore dia-
meters of 0.20 μm. Aliquots of 20 μl were injected into
the LC/MS system. The quantitative range of this
method was 5-500 ng/ml.
Statistical analysis
T h ea r e au n d e rt h ec u r v ef r o mt h ed r u g( S - 1o rG E M )
administration to the infinite time (AUCinf) was
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WinNonlin program (Ver. 5.2; Pharsight Co., Mountain
View, CA, USA). Two-sided paired Student’s t-test on
log-transformed plasma concentration data was used to
compare the maximum concentration (Cmax) and
AUCinf between single administration and co-adminis-
tration. The two-sided paired Student’s t-test was con-
ducted on the elimination half-life (T 1/2) and time
required to reach Cmax (T max) in order to compare
data for single administration and co-administration. A
P value of < 0.05 was considered to be statistically
significant.
Results
Clinical outcome
Five of six patients were treated by GEM+S-1 for 5 to
16 courses (median, 8 courses). However, it was neces-
sary to reduce the doses of S-1 and/or GEM by approxi-
mately 25% due to grade 3 or more neutropenia for two
patients after one course, and for two patients after
three courses. The regimen was stopped at the end of
one course in one patient who could not continue oral
intake of S-1 due to developing the stenosis at Treitz
ligament by cancer invasion. The MST of total patients
studied was 12.5 months, ranging from 3 to 22 months.
The 1-year survival rates were 67%. One partial response
was observed. SPan-1, one of reliable tumor marker for
pancreatic cancer [9], titers in sera were decreased 50%
or more in all of 5 patients who had abnormal level of
SPan-1 prior to the treatment.
Plasma PK
There were no significant differences between plasma
PK parameters of GEM after administration of GEM
a l o n ea n dG E M + S - 1( T a b l e1 ,F i g u r e2 ) .T h e r ew e r en o
significant differences between the plasma PK para-
meters of 5-FU after administration of S-1 alone and
GEM+S-1 (Table 2, Figure 3).
Discussion
For the last decade, GEM monotherapy has been the
standard chemotherapy regimen to treat advanced pan-
creatic cancer. The drug has an approximately 5%
response rate and improves MST to less than 6 months
[10]. Clinical trial data has demonstrated a response rate
of 44-48% and an MST of 10.1-12.5 months when S-1 is
administrated with GEM [6,7]. The efficacy of this com-
bination therapy, including our regimen, thus appears to
Figure 1 Drug administration and blood sampling schedule.
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luation requires data from the ongoing phase III trial
(GEST study).
Our results demonstrated that pre-administration of
S-1 did not increase Cmax, AUCinf or T1/2 of plasma
GEM (Table 1, Figure 2). Nakamura et al. performed a
PK study of GEM with S-1; S-1 was given orally at a
dose of 30 mg/m
2 twice daily for 14 consecutive days,
followed by a 1-week rest. GEM 1000 mg/m
2 was given
in a 30-min i.v. on day 8 and day 15. In six patients
with metastatic pancreatic cancer, the PK parameters of
Cmax and AUCinf for GEM were examined on day 8. It
was concluded that their data were similar to those of
GEM single-administration, as determined in a phase I
study [11] carried out by other investigators [12].
Table 1 Comparison of pharmacokinetic parameters of
gemcitabine (GEM) in plasma between administraion of
GEM alone and GEM+S1
Cmax (ng/ml) AUCinf (hXng/ml) T1/2 (h)
Day 1 15833 ± 2477 8467 ± 1092 0.12 ± 0.033
(GEM alone)
Day 15 14924 ± 5828 8384 ± 2915 0.153 ± 0.069
(GEM+S-1)
P-value 0.604 0.7406 0.1594
GEM was intravenously given at a dose of 800 mg/m2. S-1 was orally given at
a dose of 30 mg/m2.
Cmax, maximum plasma concentration;
AUCinf, area under plasma concentration-time curve from time zero to infnite
time; T1/2, elimination half-life.
Titers are expressed as means ± SD (n = 6). P-values were examined by two-
sided paired t-test after log-transformation.
Figure 2 Plasma concentrations of gemcitabine (GEM) after administration of GEM 800 mg/m
2 alone (open circles) and GEM 800 mg/
m
2 + S-1 30 mg/m
2 (closed circles).
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ever, the ethical matters limit the sample size. There
have been some reports statistically comparing the PK
parameters between two groups composed of five or six
patients [13,14]. In our study on six patients, the statisti-
cal analysis was done to detect the relative change of the
PK parameters in individual patients using the paired
Student’s t-test. In this analysis, the statistical power
depends on the intra-individual variance and not on the
inter-individual variance.
Correale et al.r e p o r t e dt h a tp r e - a d m i n i s t r a t i o no f
GEM had an effect on the plasma PK of 5-FU [15]. In
their study, 20 patients with metastatic gastroenteric car-
cinomas were treated with 30 min i.v. of 5-FU 400 mg/
m
2 and folinic acid (FA) 100 mg/m
2 at 1 h after 30 min i.
v. of GEM 1000 mg/m
2. The control group (5-FU/FA
group) consisted of 16 patients with gastroenteric carci-
nomas receiving 30 min i.v. of 5-FU 400 mg/m
2 and FA
100 mg/m
2. The AUC of plasma 5-FU in GEM+5-FU/FA
group was approximately twice as high as that in 5-FU/
FA group. The Cmax and T1/2 of 5-FU in GEM+5-FU/
FA group were higher than those in 5-FU/FA group. The
enhanced 5-FU systemic exposure in the presence of
GEM may induce severe adverse events as well as high
levels of antitumor activity. In fact, a clinical phase I/II
trial testing GEM+5-FU/FA for 51 patients with gastro-
enteric cancers reported frequent grade 4 gastroenteric
toxicity and two treatment-related deaths [15].
In contrast to the study by Correale et al., in our
examination, the plasma Cmax, AUCinf and T1/2 of 5-
FU after co-administration of S-1 with GEM showed no
increases when compared to those after S-1 single-
administration (Table 2, Figure 3). Although significant
differences were not shown, the mean values of Cmax
and AUCinf of 5-FU at day 15 were lower than those at
day 3 (Table 2). The reason is obscure, however, contin-
uous administration of S-1 might affect 5-FU
pharmacokinetics.
In the catabolic pathways, 5-FU is degraded by DPD.
As S-1 contains a very strong DPD inhibitor, CDHP, the
Cmax and AUCinf of plasma 5-FU after S-1 administra-
tion may reach the limit expected by the amount of tega-
fur present in S-1. The affects of GEM metabolites on
Cmax and AUC of plasma 5-FU after S-1 administration
may be little lower than expected based on the presence
of CDHP in plasma. The above-mentioned mechanism
may explain our results that PK parameters of plasma 5-
FU after S-1 administration did not differ with and with-
out GEM administration. Moreover, no enhancement of
5-FU systemic exposure after S-1 administration in the
presence of GEM may be an advantage in reducing the
frequency of adverse events [16].
The synergistic effects of S-1 and GEM may be
explained by the following mechanism occurring in
Table 2 Comparison of pharmacokinetic parameters of
5-fluorouracil in plasma between administration of S-1
alone and gemcitabine (GEM)+S1
Cmax
(ng/ml)
AUCinf
(hXng/ml)
T1/2 (h) Tmax (h)
Day 3 162 ± 46 853 ± 329 1.96 ± 0.73 3.16 ± 0.81
(S-1 alone)
Day 15 135 ± 56 682 ± 256 2.22 ± 0.84 3.07 ± 0.53
(GEM+S-1)
P-value 0.8644 0.2063 0.604 0.1683
GEM was intravenously given at a dose of 800 mg/m2 S-1 was orally given at
a dose of 30 mg/m2.
Cmax, maximum plasma concentration;
AUCinf, area under plasma concentration-time curve from time zero to infnite
time; T1/2, elimination half-life; Tmax, the time required to reach Cmax.
Titers were expressed as means ± SD (n = 6). P-values were examined by two-
sided paired t-test after log-transformation.
Figure 3 Plasma concentrations of 5-fluorouracil after
administration of S-1 30 mg/m
2 alone (open circles) and GEM
800 mg/m
2 + S-1 30 mg/m
2 (closed circles).
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bolite of 5-FU is fluorodeoxyuridine monophosphate
(FdUMP), which inhibits DNA synthesis by forming of
ternary complex with 5,10-methylene tetrahydrofolate
and thymidylate synthase. GEM inhibits ribonucleotid
reductase, a key enzyme in the salvage pathway of pyri-
midine biosynthesis. Consequently, GEM reduces the
synthesis of deoxyuridine monophosphate, a major com-
petitor of FdUMP, resulting enhancement of 5-FU cyto-
toxicity [17]. Another potential mechanism is that 5-FU
leads to an increase in cell surface human equilibrative
nucleoside transporter 1 (hENT1) [18,19]. The most
active GEM uptake is via hENT1. Thus, increased
hENT1 expression by 5-FU may augment GEM cyto-
toxicity by increasing GEM concentrations in tumor
cells.
In conclusion, the present study obtained by the lim-
ited number of patients demonstrated the combination
chemotherapy of S-1 with GEM did not affect the PK of
each drug. As S-1 combined with GEM may be a pro-
mising regimen, further investigations should be carried
out to elucidate the synergistic mechanisms between the
two drugs.
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